Phase II Trial of RAD001 in Refractory Colorectal Cancer

Swedish Medical Center

Status and phase: Completed; Phase 2

Conditions: Colorectal Cancer

Treatments: Drug: RAD001

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00337545

CRAD0012467

Swedish Cancer Institute 05128

Details and patient eligibility

About

Single center open-label study of an oral agent (RAD001) in subjects with metastatic colorectal cancer refractory to at least 2 standard chemo/biologic regimens.

Full description

Study is completed and closed.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens
• Measurable disease
• ECOG 0-2

Exclusion criteria

• CNS disease
• Chemotherapy or radiotherapy < 4 weeks prior
• Active bleeding diathesis

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)